Syros Pharmaceuticals, Inc. (SYRS) Upgraded to Buy: What Does It Mean for the Stock?

This article was originally published on Nasdaq

Syros Pharmaceuticals, Inc. (SYRS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.

Responses